The Smithers Group announced today the formation of
Smithers Pharma Services, pulling together under one brand what had been
Synomics Pharma Services and SP Formulations. This change enables clients
across the globe to interact with one organization, and creates an easy and
more efficient way for customers to access a broader range of drug development
and testing services.

“By combining two business units with specialized
expertise into one unified company, we can deliver a customized, collaborative
solution that solves our clients’ unique drug development challenges.”
said Michael Hochschwender, President and Chief Executive Officer of The Smithers
Group.

Smithers Pharma Services represents the combined activities
of the previous brands, and provides formulation services, analytical chemistry,
and pre-clinical and clinical bioanalytical testing, while offering further
drug development support through in-house storage stability studies, for the pharmaceutical,
biotechnology, and consumer product industries.